Biosimilar Antibodies

Lotivibart is a human monoclonal antibody of the IgG1κ subtype designed to specifically target the gp120 envelope glycoprotein. For experimental control purposes, the recommended isotype control is Human IgG1 kappa Isotype Control.

Trosunilimab is a chimeric humanized antibody of the IgG1κ isotype, designed to specifically target ITGA4_ITGB7. For experimental control purposes, the recommended isotype control is Human IgG1 kappa.

Firastotug is an IgG1κ monoclonal antibody specifically designed to target CTLA-4, a critical immune checkpoint protein associated with cytotoxic T lymphocytes. CTLA-4 plays a pivotal role in regulating immune responses, making it a significant target in the study of autoimmunity and oncology. This antibody is instrumental for researchers focusing on the modulation of immune checkpoints to understand disease mechanisms and develop therapeutic strategies.

Petosemtamab (MCLA 158) is a bifunctional monoclonal antibody targeting both EGFR and LGR5 with dissociation constants (Kd) of 0.22 nM and 0.86 nM, respectively. This antibody effectively blocks EGFR signaling and induces receptor degradation specifically in LGR5-positive cancer cells. Petosemtamab is primarily utilized in research focused on solid tumors, including head and neck squamous cell carcinoma (HNSCC) and metastatic colorectal cancer (CRC), providing a valuable tool for investigating the pathophysiology and potential therapeutic strategies for these malignancies.

Denecimig (Mim8) is an innovative bispecific human antibody engineered to mimic activated coagulation factor VIII. It features dual specificity with anti-FIXa and anti-FX arms, effectively enhancing the activation of Factor X. This potent stimulation of FX activation facilitates efficacious hemostasis both in vitro and in vivo, making it a valuable tool for research in coagulation and hemostatic processes.

Umikibart is a humanized IgG4κ monoclonal antibody specifically targeting HGF (hepatocyte growth factor). For experimental controls, it is recommended to use Human IgG4 (S228P) kappa as an isotype control. This specificity and configuration make Umikibart suitable for detailed studies in HGF-related pathways and potential therapeutic applications.

Fazpilodemab (BFKB8488A) is a humanized, agonistic, bispecific antibody designed to specifically target fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. This antibody is engineered for the investigation of metabolic disorders, particularly type 2 diabetes mellitus (T2DM) and nonalcoholic fatty liver disease (NAFLD). Fazpilodemab's dual targeting mechanism facilitates the study of signaling pathways that may play critical roles in the pathophysiology of these conditions.

Ansipastobart is a human monoclonal antibody of the IgG1λ2 subtype that specifically targets NT5E. For experimental control purposes, the recommended isotype control is Human IgG1 lambda2.

The Anti-INHBB/Activin B Antibody is a human monoclonal antibody produced in Chinese Hamster Ovary (CHO) cells, specifically targeting INHBB/Activin B. This antibody is composed of a human IgG1 type heavy chain and a human kappa type light chain, with an estimated molecular weight of 150 kDa. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is ideal for research applications focusing on the biological functions and regulatory mechanisms of INHBB/Activin B.

Velaprumig is a monoclonal antibody engineered to target human CD99, CCL25, and Aβ-47F, a specific epitope of the amyloid beta peptide. This antibody plays a crucial role in regulating immune cell migration and attenuating pathological processes associated with β-amyloid deposition. Its dual action not only serves as an immunomodulator but also offers potential therapeutic benefits in the treatment of Alzheimer’s disease by targeting key mechanisms implicated in its pathogenesis. Velaprumig is suitable for a range of research applications focused on the study of immune response and neurodegenerative diseases.

The Anti-LY6G6D Antibody (1G4) is a humanized IgG1 monoclonal antibody specifically designed to target LY6G6D, a member of the LY6/uPAR family involved in various cellular processes. This antibody is ideal for researchers focusing on cell signaling and immune response studies. For accurate experimental control, it is recommended to use Human IgG1 kappa Isotype Control.

Rovalpituzumab is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3), a protein expressed in neuroendocrine tumors including small cell lung cancer (SCLC). This antibody serves as a foundational component in the development of the antibody-drug conjugate (ADC), Rovalpituzumab Tesirine, designed for targeted cancer therapy. Rovalpituzumab exhibits specific activity against SCLC, providing a strategic tool for research and therapeutic development in oncology.

The Anti-Hepcidin/HAMP Antibody is a recombinant human monoclonal antibody produced in Chinese hamster ovary (CHO) cells, specifically designed to target Hepcidin, also known as HAMP. This antibody is composed of a human IgG1 heavy chain and a human lambda light chain, and exhibits a predicted molecular weight of 145 kDa. For isotype control purposes, Human IgG1 kappa, Isotype Control is recommended. This product is suitable for a range of research applications, focusing on the study of Hepcidin's role in iron metabolism and related disorders.

Upifitamab serves as an ADC (antibody-drug conjugate) antibody, specifically the unconjugated form of upifitamab rilsodotin, designed for the synthesis of antibody-coupled agents. Upifitamab rilsodotin targets the sodium-dependent phosphate transport protein 2b (NaPi2b), and is predominantly utilized in the study of platinum-resistant recurrent ovarian cancer. This application highlights its potential in advancing therapeutic strategies and understanding disease mechanisms in oncology research.

ARGX-119 is a pioneering humanized agonist monoclonal antibody that selectively targets muscle-specific kinase (MuSK). This antibody is particularly useful for the investigation of neuromuscular diseases, providing a critical tool for understanding the pathophysiology and potential therapeutic interventions in these disorders. For isotype control purposes, researchers should use Human IgG1 lambda1, Isotype Control, which serves as a standard for experimental consistency and validation.

SAR442257 is a humanized IgG4-S228P kappa monoclonal antibody designed to specifically target CD38 and CD28 antigens expressed on multiple myeloma cells. Additionally, this antibody co-stimulates CD3 and CD28 on T cells, enhancing immune response. This dual targeting and co-stimulation mechanism makes SAR442257 a valuable tool for research in immunotherapy and the study of multiple myeloma pathogenesis.

IMM-20059 is a humanized IgG1 monoclonal antibody specifically targeting EPN1. When used in conjunction with Atezolizumab, IMM-20059 has demonstrated a significant enhancement in tumor regression within the B16.F10 syngeneic melanoma model, surpassing the efficacy observed with anti-PD-L1 monotherapy. This product is pivotal for research focused on innovative cancer treatment modalities and the exploration of synergistic therapeutic combinations.

Cobolimab (TSR-022) is a monoclonal antibody targeting the T-cell immunoglobulin and mucin-domain containing-3 (TIM-3). This antibody facilitates the internalization of TIM-3, exhibiting potent activity with an IC50 value of 0.4464 nM. Cobolimab is primarily investigated for its therapeutic potential in the treatment of solid tumors and non-small cell lung cancer (NSCLC), highlighting its relevance in oncological research and therapeutic applications.

Nuvustotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets TNFRSF4. For experimental control purposes, it is recommended to use Human IgG1 kappa as the isotype control.

The Anti-CD28 Antibody (9.3) is a chimeric mouse IgG2a antibody designed to specifically target human CD28. This antibody serves as a crucial tool for the modulation and study of CD28 signaling pathways, which are vital in T-cell activation and immune response. For accurate experimental control, it is recommended to use Mouse IgG2a kappa as an isotype control. This antibody is suitable for a variety of immunological applications, including flow cytometry, immunoprecipitation, and other assays requiring precise CD28 targeting.

Solnerstotug is a human monoclonal antibody of the IgG1κ subtype that specifically targets V-set immunoregulatory receptor (VSIR). For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies focused on immune regulation and VSIR-mediated pathways.

Concizumab, an IgG4 subtype monoclonal antibody, targets the Kunitz-type protease inhibitor 2 (KPI-2) structural domain of tissue factor pathway inhibitor (TFPI). By binding to this domain, Concizumab effectively inhibits the interaction between TFPI and the Factor Xa (FXa) active site. This antibody is particularly useful for research in hemophilia, providing insights into novel therapeutic interventions targeting coagulation pathways.

Stapokibart (CM310) is a humanized monoclonal antibody specifically designed to target IL-4Rα, effectively inhibiting the binding of cytokines IL-4 and IL-13 to their co-receptor subunit IL-4Rα. This antibody demonstrates cross-species reactivity, interacting with IL-4Rα in humans, cynomolgus monkeys, and rats, making it a versatile tool for diverse biological research settings.

Obertamig is a humanized monoclonal antibody engineered to target CD3E and HLA-G. It features modifications in the CH2-CH3 regions and is composed of a hybrid structure that includes half of an immunoglobulin IgG1 λ2 and a single-chain variable fragment (scFv). This design enhances its specificity and efficacy in binding to its designated antigens, making it an ideal candidate for research in immune response modulation and therapeutic applications targeting these molecules.

VIS-410 is a fully human monoclonal antibody of the IgG1 subclass that specifically targets the influenza A virus. For experimental control purposes, the recommended isotype control is Human IgG1 kappa, Isotype Control. This antibody is designed for use in research studies aimed at understanding and potentially mitigating the impact of influenza A infections.

Volagidemab is a monoclonal antibody designed to act as an antagonist to the glucagon receptor (GCGR). This antibody is specifically developed for use in research focused on Type 1 Diabetes (T1D), providing a critical tool for investigating the role of GCGR in glucose regulation and diabetic pathology.

Efungumab is a monoclonal antibody characterized by its potent antifungal properties. This antibody specifically targets and binds to Heat Shock Protein 90 (HSP 90), a critical component in fungal cell viability. By binding to this protein, Efungumab inhibits a necessary conformational change, thereby compromising fungal cell survival. This mechanism of action makes Efungumab an invaluable tool for research focused on invasive candidiasis (IC), providing insights into fungal pathogenesis and potential therapeutic interventions.

Sontuzumab (AS1402) is a humanized IgG1κ monoclonal antibody that exhibits high specificity for the MUC1 antigen, targeting the extracellular peptide sequence PDTR with a dissociation constant (Kd) of approximately 1 nM. This antibody is primarily utilized in the research of breast cancer, providing a valuable tool for the study of MUC1-related oncogenic pathways and potential therapeutic interventions.

Voxalatamab (JNJ-63898081) is a bispecific IgG4 monoclonal antibody designed to target both PSMA (Prostate-Specific Membrane Antigen) and CD3. This antibody exhibits anticancer activity and is specifically developed for research in prostate cancer. Voxalatamab facilitates the engagement of T-cells to PSMA-expressing tumor cells, offering a strategic approach for investigating immune-mediated cancer cell eradication.

Anti-CD98 monoclonal antibody (Clone KHK2898) specifically targets CD98, a protein implicated in amino acid transport and integrin signaling. This antibody is ideal for research applications aiming to elucidate the role of CD98 in cellular processes such as nutrient uptake, cell adhesion, and tumor progression.

Omburtamab is a monoclonal antibody targeting CD276, also known as B7-H3, which is a member of the B7/CD28 immunoglobulin superfamily. CD276 is prominently expressed in a variety of solid human tumors. This antibody has the capability to specifically bind to tumor tissues, making it a valuable tool for research in cancer biology and therapeutic development across multiple cancer types.

hT84.66-M5A is a humanized IgG1 monoclonal antibody specifically designed to target the carcinoembryonic antigen (CEA), a widely studied tumor marker implicated in various types of cancers. This antibody mimics the natural immune response against tumor cells expressing CEA, making it an essential tool for research in oncology and cancer diagnostics. The recommended isotype control for hT84.66-M5A is Human IgG1 kappa, which serves as a critical baseline to validate the specificity and ensure the accuracy of immunoassays involving this antibody.

Bapotulimab (BAY-1905254) is a fully humanized IgG2 monoclonal antibody designed to specifically target the immunoglobulin-like domain containing receptor 2 (ILDR2). This antibody exhibits potent antitumor activity and immunosuppressive properties, making it a valuable tool for research in cancer immunotherapy and immune regulation.

Tixagevimab (AZD8895) is a human monoclonal antibody designed to target the receptor binding domain (RBD) of SARS-CoV-2. It effectively neutralizes the virus by binding to the RBD as well as the S-glycoprotein ectodomain, thereby inhibiting the S-glycoprotein-mediated attachment to the host cell receptor. This antibody is pivotal for research focused on the mechanisms of viral entry and the development of therapeutic strategies against SARS-CoV-2.

Zifibancimig is a monoclonal antibody of the IgG1κ isotype, designed to target and neutralize both VEGFA (Vascular Endothelial Growth Factor A) and ANGPT2 (Angiopoietin-2). This dual specificity makes it a valuable tool for investigating the complex interplay between these two critical angiogenic factors in various pathological conditions. Zifibancimig is utilized primarily in research focused on angiogenesis, tumor growth, and vascular diseases.

Linvoseltamab (REGN5458) is a bispecific T-cell engager (BiTE) antibody designed to selectively bind to the B cell maturation antigen (BCMA) on the surface of multiple myeloma (MM) cells and the CD3 receptor on T cells. This dual binding facilitates the targeted destruction of MM cells by directing and activating T cells to recognize and eliminate BCMA-expressing tumor cells. Linvoseltamab is primarily utilized in research focused on relapsed or refractory multiple myeloma (RRMM), providing a valuable tool for investigating novel therapeutic strategies in this challenging clinical area.

Galcanezumab (LY 2951742) is a humanized IgG4 monoclonal antibody designed to specifically target and neutralize the calcitonin gene-related peptide (CGRP) ligand. This antibody is utilized extensively in research focused on migraine and cluster headaches, providing a valuable tool for investigating the pathophysiology and potential therapeutic interventions for these conditions.

Mupadolimab (CPI-006) is a humanized IgG1κ monoclonal antibody designed to selectively target CD73 with modified FcγR binding properties to reduce effector function. This antibody is engineered to activate CD73-positive B cells, playing a crucial role in modulating immune responses. Its unique mechanism and specificity make it an invaluable tool for research focused on immunology and oncology, particularly in studies exploring the regulation of the immune checkpoint pathways.

Tomaralimab (OPN-305) is a humanized IgG4 monoclonal antibody targeting Toll-like receptor 2 (TLR2). This antibody is designed for investigational use in the study of Myelodysplastic Syndromes (MDS), offering potential insights into the role of TLR2 in the pathogenesis of this condition.

Ravulizumab (ALXN1210) is a humanized monoclonal antibody engineered to bind with high affinity to the human complement protein C5. This antibody is pivotal in the inhibition of the terminal complement cascade, a key component in immune response and inflammation. Ravulizumab is primarily utilized in the investigation of diseases such as paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis, offering a significant tool for understanding the pathophysiology and therapeutic interventions of these conditions.

Iparomlimab is a monoclonal IgG4κ antibody that targets the human programmed death-1 receptor (PD-1, also known as CD279 or PDCD1). This antibody is engineered to bind specifically to the PD-1 receptor, a critical molecule involved in the negative regulation of immune responses and a key therapeutic target in oncology. Iparomlimab is composed of a γ4-chain and a κ-chain of the human monoclonal antibody PSB103, linked by a disulfide bond to form a stable dimer. This biologic is primarily utilized in research focused on cancer immunotherapy, investigating the modulation of immune checkpoints that are pivotal in tumor immune evasion.

Mogamulizumab (KW-0761) is a recombinant monoclonal antibody that targets CC chemokine receptor 4 (CCR4). This antibody facilitates the elimination of tumor cells through antibody-dependent cellular cytotoxicity (ADCC), a critical mechanism for immune-mediated tumor cell eradication. Mogamulizumab is primarily utilized in the investigation of various cancers, including adult T-cell leukemia/lymphoma (ATLL) and cutaneous T-cell lymphoma (CTCL), providing a valuable tool for research in oncology and immunotherapy.

Anselamimab (CAEL-101) is a humanized IgG1-κ monoclonal antibody designed to specifically target serum amyloid A1 (SAA1) amyloid fibrils. This antibody binds with high affinity to the SAA1 amyloid fibrils, a key pathological component in amyloidosis disorders, thereby offering potential for therapeutic intervention and disease-modifying effects in amyloid-related diseases. Anselamimab is utilized primarily in research focused on the pathogenesis and treatment of amyloidosis, making it a valuable tool for both basic research and clinical development studies.

Divozilimab (BCD-132) is a humanized monoclonal antibody specifically targeting CD20, a cell surface protein primarily expressed on B lymphocytes. This antibody is utilized extensively in the study of multiple sclerosis, aiding in the exploration of B-cell mediated pathogenesis and potential therapeutic interventions.

Tarlatamab (AMG-757) is a first-in-class, half-life extended (HLE) bispecific T-cell engager (BiTE) antibody designed for targeted immuno-oncology applications. This therapeutic antibody specifically targets delta-like ligand 3 (DLL3), a protein predominantly expressed in small-cell lung cancer (SCLC) cells, with minimal expression in healthy tissues. Tarlatamab exhibits high binding affinities with dissociation constants (K_Ds) of 0.64 nM for human DLL3 and 0.50 nM for nonhuman primate (NHP) DLL3. Additionally, it shows binding affinities of 14.9 nM and 12 nM for human and NHP CD3, respectively. The selective targeting of DLL3 and the engagement of CD3, a critical component of the T-cell receptor complex, make Tarlatamab a promising candidate for the study and potential treatment of SCLC.

Axatilimab (SNDX-6352) is a humanized IgG4 monoclonal antibody designed to selectively bind with high affinity to colony-stimulating factor 1 receptor (CSF-1R). This antibody is primarily utilized in research focused on chronic graft versus host disease (cGVHD) and various neoplastic diseases, providing a valuable tool for studies aimed at elucidating the role of CSF-1R in these complex conditions.

Comekibart is a humanized IgG4κ monoclonal antibody specifically targeting the IL4 receptor (IL4R). For experimental control purposes, it is recommended to use Human IgG4 (S228P) kappa as the isotype control. This specificity and isotype matching ensure accurate and reliable results in research applications focusing on the modulation and study of IL4R-mediated signaling pathways.

Dafsolimab (SPV-T3a) is a murine monoclonal antibody of the IgG2a subclass, targeting the CD3 antigen on T cells. This antibody functions by modulating and activating the CD3/T cell receptor complex, subsequently inducing T cell death. Dafsolimab is primarily utilized in research focused on understanding and treating graft-versus-host disease (GVHD), offering significant insights into T cell behaviors and immune responses in this condition.